Navigation Links
Savara Expands Board of Directors, Appoints Three New Members

Nevan Elam, Former Head of Nektar Therapeutic's Pulmonary Business Unit, Among New Board of Directors Members

AUSTIN, Texas, March 4 /PRNewswire/ -- Savara, Inc., a biopharmaceutical company developing novel respiratory therapeutics utilizing its NanoCluster dry-powder formulation technology, today announced that it has expanded its Board of Directors and elected three new members.

Nevan Elam, former head of the pulmonary business unit at Nektar Therapeutics, has been appointed to fill a seat previously held by Cory Berkland, Ph.D. The board has also been expanded from three members to five, with Curt Bilby, Ph.D., and Matthew Dennis filling the new seats.

"We are honored to have these new members join the Board of Directors," said Rob Neville, Executive Chairman of the Board of Savara. "Their experience, including Mr. Elam's proven track record in the pulmonary drug delivery space, will provide an essential perspective as we respond to increasing interest in our platform NanoCluster technology."

"Savara's formulation technology combines the features of nanoparticles in structured microparticles to yield a powder with ideal aerodynamic properties for inhalation. Their approach is unique and addresses many of the challenges associated with existing formulation technologies. I am excited to be a part this company and to help guide the next generation pulmonary drug delivery technology," said Mr. Elam.

Mr. Elam, 41, is a former member of the executive management team of Nektar Therapeutics where he served as senior vice president, head of the pulmonary business unit. In this role, he oversaw all pulmonary business including research and development, manufacturing and strategic partnerships. Most recently Mr. Elam was responsible for the sale of Nektar's pulmonary business to Novartis for $115 million on Dec. 31, 2008.

Dr. Bilby, 49, is president & CEO of Terapio, a pharmaceutical company developing a pipeline of protein-based therapeutics. He is a four-time biotechnology CEO with more than 20 years of entrepreneurial leadership and executive management experience - both domestically and in Europe. Dr. Bilby also serves as Chairman of BioAustin.

Mr. Dennis, 41, is currently senior director of International Equities, Invesco AIM. As a global equity strategist, he has extensive experience analyzing business models, corporate strategies and market trends with a particular emphasis on the European pharmaceutical industry. He is involved in several different funds and mandates with a collective net asset value of approximately $11 billion, and is directly responsible for managing $6 billion of international and global equity assets.

About Savara, Inc.

Savara ( is developing next generation pulmonary drug delivery solutions using its NanoCluster formulation technology, which is now available for evaluation and license. Medicines manufactured using the NanoCluster technology are formulated directly from nanoparticle actives without the need for carrier particles or spray drying. The aerodynamics of NanoCluster formulations are fully customizable and permit targeted deposition of medicines to specific lung regions, including the deep lung. Savara expects that these NanoCluster features will translate into numerous patient benefits including reduced doses, enhanced efficacy, improved safety and tolerability as well as greater patient convenience.

    Contact Information

    Ian Stone
    Russo Partners, LLC
    (619) 528-2220

    Josef Bossart
    (512) 535-3613

    Rob Neville
    (512) 970-4740

SOURCE Savara, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Medical Affairs Company Expands Its Medical Communications Division
2. Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia
3. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
4. CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer
5. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
6. Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Yourway Transport Expands Biological Services
9. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
10. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
11. Yourway Transport Expands
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):